Ruti Aga's Six-Year Ban: The Forged Prescription, the Misclassified Drug, and the Full Arithmetic of the Sanction

Six Years, Two Lines, and One Word Printed Wrong

On Thursday afternoon the Athletics Integrity Unit's statement arrived. It contained two dates and one number. The date: 10 September, from which Ruti Aga had been provisionally suspended. The number: six years. Between them lay a story that is not as clean as it sounds — she won a half marathon in China in March, the in-competition sample returned methylprednisolone, she cited a knee injury, and the prescription turned out to be forged. The person who issued it was not a doctor but a family member, who said during questioning that he had used "an old prescription pad from a former workplace." The clinic named on the document did not exist.

The second line of that same statement carries the real architecture: two years for presence of the substance, four years for tampering. Six in total. That sum is not mere sentencing detail; it is a map of the panel's reasoning, and it shows precisely which argument was accepted and which was rejected.

Then there is the word repeated in almost every report — "prohibited steroid." Methylprednisolone is not a steroid in the sense that word plants in a reader's mind. It is a glucocorticoid, WADA Prohibited List class S9, and the defining condition of that class is that it is prohibited in-competition only — by injection, oral or rectal route. A therapeutic knee injection given out of competition is entirely lawful. It becomes a violation only when residues are present in an in-competition sample.

That correction matters because it moves the entire case. Had this been an anabolic steroid, the argument would be about cheating. Because it is a glucocorticoid, the argument must be about route and timing — the one question genuine medical records could have answered and a forged prescription could never.

Context: The Chinese Label Race, the Appearance-Fee Economy, and My Archive

Ruti Aga is a 32-year-old Ethiopian marathoner. She won the 2026 Tokyo Marathon, a World Marathon Major. She was second in Berlin in 2026. She has three second-place finishes at the Majors. That is a record read with respect before any selection committee and with hesitation before any sponsorship board.

One clarification, because the statement does not contain it: the year, the time and the placing of the March Chinese half marathon are not in the source. All that is given is that she won it and was tested in-competition afterwards. I have kept a discipline across twenty-three years of notebooks — no performance claim is built on a number absent from the file. So there is no split analysis here, no field-strength estimate. What follows is the administrative chain.

To understand that chain you need the ecosystem the race sat in. For East African marathoners the Majors are two or three races a year; the months between them are funded by Asian label races — China, Japan, Korea. Appearance fees are good, fields are manageable, weather is workable. For a 2:18–2:20 athlete, this is the low-risk, decent-yield tier: a paid week between Major preparations.

I open that economics because it is the geography of this case. In 2026, when the national camp resumed at NIS Patiala among empty stands, I wrote a series on the ledger. The conclusion then still anchors my work: empty stadiums do not empty the ledger; they move the cost. Here the cost has moved. The expense of Major preparation has shifted to the Asian label circuit, and the testing pressure has shifted to the same place.

Why? Because money is large there, the elite field is deep, and the sampling tool is present. In road racing the in-competition window opens at 23:59 the night before. That technicality is decisive here. If a knee injection was given days before the race and residues remained on race day, medically legitimate work becomes a rule violation. This case is less about a drug than about a timetable.

I should date my own method here. At the 2026 Asian Athletics Championships in Bhubaneswar I watched a javelin result and started a spreadsheet that night — every Indian mark from 2026 to 2026, with columns for release angle and block-leg stability. I wrote then that one meet's data is not a trend. The same habit applies: the raw sheet held two stories; I followed the one with a receipt.

At the 2026 Commonwealth Games in Gold Coast I was in the commentary booth when the men's 4x400 relay selection row broke. I opened the rulebook, read the selection criteria, interviewed the coach, and wrote the baton-exchange rules line by line. The report was dry. It was also correct. A selection review is a paper trail with consequences, not a ceremony. An anti-doping decision is the same object — a document chain whose every link can be weighed separately.

Core Analysis: The S9 Condition, and the Defence the Forgery Destroyed

First layer — classification

Methylprednisolone is a corticosteroid used to suppress inflammation. In distance running, intra-articular injection for knee synovitis is ordinary sports medicine. WADA lists it under S9, and since 2026 that class has been clearly bounded: in-competition only, and only by injection, oral or rectal route.

The consequence is straightforward. An athlete who takes a documented knee injection out of competition, on medical advice, and observes an adequate washout has done nothing wrong. Even if the washout was inadequate, the defence does not close — genuine records showing date, dose, route and the physician's registration number support a no-fault or no-significant-fault argument, and the sanction can fall to a reprimand or a shortened period.

Aga had that route open. The knee claim is not inherently implausible; chronic knee pathology is a known load-bearing failure mode in high-volume marathoners. The injury story was physiologically credible and legally fatal — not because it was false, but because the paper needed to prove it was manufactured.

Second layer — three verification failures

The AIU statement describes a chain that breaks at three separate points.

The person: the prescriber was a family member, not a registered physician. That is not a clerical defect. It signals the absence of a credentialed team physician.

The institution: the clinic named on the prescription did not exist.

The explanation: questioning produced the claim of an "old prescription pad from a former workplace," which the clinic explicitly disowned.

Three levels, three people, three moments. For any investigator this is not the threshold of suspicion; it is the threshold of proof. It is also why the four-year tampering sanction is hard to attack — it rests on documents, not testimony.

Here I record what the file does not contain, because silence is a finding. Only the family member is named. No action against an agent, manager or training-group member appears in the statement. Whether they were outside the investigation or cleared by it is unknown. The file is silent, and I treat the silence as part of the record.

Third layer — the arithmetic

Two years for presence. That figure matches a finding where intent is not established, treating the substance as Specified and reducing the standard sanction. In plain terms: the panel did not find that she took it to enhance performance.

Four years for tampering. The Code's standard sanction, applied to an act separate from the drug — submitting a fabricated document during an investigation. The two add; they do not offset.

The sum tells us something more: the panel rejected the no-significant-fault mitigation. Had that relief been granted, the presence sanction could have fallen well below two years. It was not granted for the reason every investigator knows — an athlete who fabricates documents destroys the credibility of his or her own defence.

There is a paradox I will leave open, because the statement does not resolve it. A forged document is itself circumstantial evidence of concealment intent. Yet it did not aggravate the presence sanction; it merely added a separate charge. The panel appears to have weighed the two charges on separate scales — intent-free on the drug, fully culpable on the paper — and then added the results.

Fourth layer — the defence that could have worked

Reading this as "drug caught, ban imposed" is a factual error. Three scenarios belong side by side.

Worst case, realised: six years, backdated to provisional suspension, with the March result and prize money likely voided.

Intermediate, what a competent defence achieves: genuine medical records, a clear account of injection date and route, a timing explanation. The presence charge is argued at the no-fault end, the sanction falls sharply, and no tampering charge arises at all.

Best case: a documented treatment plan, correct route, observed washout, or a TUE application where needed. No case whatsoever.

The difference across all three is not the drug. It is the paper. The day the prescription was forged, a defensible case became an indefensible one — and that is the only core conclusion in this story.

Fifth layer — backdating is procedure, not relief

Headlines report the ban as effective from 10 September, as though this were a concession. It is not. Time served under provisional suspension counts against the final sanction. The entire period since 10 September, during which she could not race anyway, is absorbed into the six years. Procedurally correct. Practically, the athlete gained nothing. Backdating is a procedural benefit, not a reduction.

Sixth layer — the career, and the age that settles it

She is 32. Six years on, she is 38.

Ethiopian women's marathon depth is not a slogan; it is a measured fact. The top tier contains women racing at world-record pace, and the queue behind them contains women whose personal bests match or beat Aga's 2:18–2:20 class. A 38-year-old returning from a six-year doping ban has no place in that queue. That is not prejudice; it is selection arithmetic.

The gap from 32 to 38 makes this sanction functionally a lifetime ban. The statement says six years. In practice it is an end date.

Seventh layer — the record that survives, and what the statement omits

Procedural rigour applies. The violation is anchored to the March race. The statement does not specify from which date prior results are annulled. Absent a finding of earlier use, results before that date are not automatically void.

Which means the 2026 Tokyo Marathon title and three Major second places remain on the record, pending any further finding. That is a genuine elite achievement and should be stated plainly, without hedging. A six-year ban does not erase the performance; it closes the road ahead of it.

A second point belongs beside it, and it weakens the claim, not the performance. Aga won no global championship medal. Her three Major second places are commercial-tier results, not championship conversions. Her removal does not move Ethiopia's medal capacity by any measurable margin.

Eighth layer — two economies colliding in one race

The structural contribution of this case sits at the tier where money moves fastest.

On one side, the appearance-fee economy: the payment circuit that draws East African elites to Asia between Majors. On the other, the testing economy: the same races, the same elite fields, the same AIU investigative teams, for whom this tier offers the highest yield.

Both economies meet on the same 21 kilometres. The race that is an athlete's easiest pay week is the investigator's easiest week. That collision will intensify, because neither side's incentive structure has changed.

Contrarian Angles

One — why the classification error matters

Yesterday's headlines said "six-year ban in steroid case." That sentence is factually wrong and materially misleading. Factually wrong because methylprednisolone is a glucocorticoid, S9, in-competition only. Materially misleading because it files this case alongside anabolic-steroid matters where intent is presumed and four years is routine. Once that filing happens, six years looks like double punishment, when in fact it is two years plus four — and the four are for paper, not for a drug.

This is not a quarrel over vocabulary. It decides which category a reader will remember this athlete in. And since media framing of East African road-running cases already runs in a groove, the error deepens it.

Two — the sanction that looks disproportionate is internally consistent

Here I have to challenge my own reflex, because it is the version of scepticism I most want to avoid.

Six years for a glucocorticoid sounds disproportionate, especially given that the class has no proven endurance benefit. Some will call it proof of AIU rigour. Some will call it disproportionate enforcement against African road runners. Both readings are half right, and both make the same mistake: they treat six as one unit. It is not. Four of the six are not for the drug. They are for the prescription. Anyone presenting this as a glucocorticoid sanction is concealing half the fact, however unintentionally. Anyone presenting it purely as a document-fraud sanction is concealing the other half, because the remaining two years attach to a substance with a legitimate medical use.

The accurate sentence is dull and therefore may never be printed: a medically plausible treatment, improperly documented, then defended with a fabricated document — together six years.

Three — the "entourage failure" story is half true, and half dangerous

A comfortable narrative is available: a 32-year-old with no credentialed medical structure, a relative who tried to help, and the athlete carrying the entire sanction.

That narrative is not wholly false. The absence of medical support is visible in the file. An athlete with a team physician has injection records, and with records there is no need to forge anything. The forgery itself proves the genuine document did not exist.

But the narrative breaks at one point, and it matters. What the investigation caught was not the drug; it was the statement. The four years attach to acts the athlete performed — submitting and defending a document during an investigation. No family member gave that account on her behalf.

Which returns us to the silence: no public action against any agent, manager or training group. If this was systemic failure, why did the scope stop where it did? The statement does not ask, so it does not answer. The question not being asked is itself a kind of answer.

Four — my own blind spot, stated plainly

I trust the archive more than the highlight reel, especially when money moves. That habit has a defect: I can mistake the document chain for the whole story, and the athlete's unwritten account drops out.

The unwritten account here: a 32-year-old running in pain, without credentialed medical help, facing one easy route — paper. She took it. It was wrong, it was expensive, and it was her decision. It is also true that she reached that route after being left in a system where no other route was visible.

That is not sympathy. It is a statement of the file's limits. The prescription does not record how much the knee hurt, for how long, or whom she asked first. What is not in the file, I do not have, and I will not fill it with inference.

Five — the question nobody is asking

Every analysis circles one question: why did she do it? The more important question is: why did nobody check a prescription bearing the name of a clinic that did not exist, for three months?

Because verification begins only when a charge exists, and a charge exists only when a sample returns positive. The system is reactive, not preventive. At a tier where appearance-fee money is fast and medical oversight is loose, a reactive system stays one step behind.

Takeaway: Five Things to Watch

The appeal window. A reasoned decision normally opens roughly 21 days, with the Court of Arbitration for Sport as forum. The forgery finding is document-based and very hard to overturn. What can move is the length of the sanction — and that requires the records this case never had.

The March result and prize money. The disqualification scope is unstated. Standard practice voids the competition at which the sample was collected and reclaims the prize money; ranking points accrued after that date would go with it.

The Ethiopian federation's silence. Only the AIU has spoken. No national statement has appeared. That silence is itself news, and if it breaks, it will show how much domestic accountability machinery exists.

The "old prescription pad" and criminal referral. Document forgery sits outside AIU jurisdiction. A national referral would take this beyond sporting discipline. No referral would signal that sporting justice is the final word on documentary crime.

The same training cluster. A forgery that reaches one athlete usually reaches others in the same group. Two more cases from this cluster in the next twelve months would establish systemic failure rather than individual lapse — and then the question stops being what one runner did and becomes who built the structure around her and who let it run.

Before I call it culture, I want to see who kept the receipts. Here there were no receipts — only an old pad, a clinic that never existed, and an account that broke three times. The next time a race at this tier is held in China and an East African runner wins it, someone should ask the question nobody has asked yet: who paid the appearance fee, and what medical paperwork travelled with the payment?